Allergan PLC. (NYSE:AGN)‘s stock had its “outperform” rating reiterated by equities researchers at Wells Fargo & Company in a note issued to investors on Monday.

A number of other research analysts also recently weighed in on the company. Royal Bank Of Canada reaffirmed a “buy” rating and set a $285.00 price target on shares of Allergan PLC. in a research note on Wednesday, September 6th. Cantor Fitzgerald reissued a “hold” rating on shares of Allergan PLC. in a report on Tuesday, August 29th. Cowen and Company reissued an “outperform” rating and set a $400.00 price objective on shares of Allergan PLC. in a report on Tuesday, August 29th. BidaskClub lowered Allergan PLC. from a “sell” rating to a “strong sell” rating in a report on Friday, August 25th. Finally, Argus reissued a “buy” rating and set a $280.00 price objective on shares of Allergan PLC. in a report on Monday, August 14th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $275.49.

Allergan PLC. (NYSE AGN) traded up 0.113% during trading on Monday, reaching $233.815. 1,339,609 shares of the company’s stock were exchanged. Allergan PLC. has a 52-week low of $184.50 and a 52-week high of $256.80. The company has a market capitalization of $78.17 billion, a price-to-earnings ratio of 7.124 and a beta of 1.18. The stock’s 50-day moving average price is $235.17 and its 200-day moving average price is $237.15.

Allergan PLC. (NYSE:AGN) last posted its quarterly earnings results on Thursday, August 3rd. The company reported $4.02 earnings per share for the quarter, topping analysts’ consensus estimates of $3.95 by $0.07. Allergan PLC. had a return on equity of 7.37% and a net margin of 79.17%. The business had revenue of $4.01 billion for the quarter, compared to the consensus estimate of $3.95 billion. During the same period in the prior year, the business earned $3.35 EPS. The firm’s revenue for the quarter was up 8.8% on a year-over-year basis. Equities analysts expect that Allergan PLC. will post $16.27 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Allergan PLC. (AGN) Rating Reiterated by Wells Fargo & Company” was posted by American Banking News and is owned by of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of US and international copyright laws. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/09/11/allergan-plc-agn-rating-reiterated-by-wells-fargo-company.html.

Several hedge funds have recently modified their holdings of the stock. Intl Fcstone Inc. purchased a new stake in shares of Allergan PLC. in the second quarter worth $1,626,000. Phocas Financial Corp. purchased a new stake in shares of Allergan PLC. in the second quarter worth $150,000. Sentry Investment Management LLC raised its position in shares of Allergan PLC. by 1.0% in the second quarter. Sentry Investment Management LLC now owns 26,889 shares of the company’s stock worth $6,536,000 after buying an additional 265 shares in the last quarter. WFG Advisors LP raised its position in shares of Allergan PLC. by 20.9% in the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after buying an additional 137 shares in the last quarter. Finally, Toronto Dominion Bank raised its position in shares of Allergan PLC. by 25.2% in the second quarter. Toronto Dominion Bank now owns 113,770 shares of the company’s stock worth $27,651,000 after buying an additional 22,873 shares in the last quarter. Institutional investors own 82.06% of the company’s stock.

Allergan PLC. Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Analyst Recommendations for Allergan PLC. (NYSE:AGN)

Receive News & Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related companies with MarketBeat.com's FREE daily email newsletter.